Literature DB >> 19027573

Comparison of in vitro safety profiles of vancomycin and cefuroxime on human corneal endothelial cells for intracameral use.

Efdal Yoeruek1, Martin S Spitzer, Oguzhan Saygili, Olcay Tatar, Tilo Biedermann, Erdal Yoeruek, Karl U Bartz-Schmidt, Peter Szurman.   

Abstract

PURPOSE: To evaluate and compare the cytotoxic and apoptotic properties of cefuroxime and vancomycin on cultured human corneal endothelial cells (HCECs) to determine their safety for intracameral use.
METHODS: Human corneal endothelial cells were harvested from human donor eyes and exposed to various concentrations of cefuroxime and vancomycin (0.15 to 15 mg/mL). For cytotoxicity testing, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test was performed. Annexin V binding combined with propidium iodide (PI) co-staining was used for the distinction of viable, early, and late apoptotic cells. Odds ratios (ORs) and confidence intervals were calculated for the control group (without drug exposure) for 2.75 mg/mL and 15 mg/mL. Cell morphology and immunolocalization of zonula occludens 1 (ZO1) were assessed after 24 hours of drug exposure.
RESULTS: Reduction in cell viability was observed in a dose-dependent manner after exposure to both drugs. Cefuroxime concentrations higher than 2.75 mg/mL and vancomycin concentrations higher than 5.0 mg/mL led to significant reduction in cell viability. The mean number of annexin V-positive and PI-positive cells was not significantly increased at 2.75 mg/mL for either antibiotic agent. After exposure to 15.0 mg/mL, however, the late apoptotic/necrotic cells predominated, with higher ORs indicating accelerated cell death. Increasing concentrations of both antibiotic agents resulted in fading immunopositivity for ZO1.
CONCLUSIONS: These data suggest a dose-dependent toxicity of cefuroxime and vancomycin on HCECs in vitro with a narrow range of safety. Although the clinically used concentrations seem to be safe, slightly higher concentrations might induce irreversible cell death and thus should be avoided.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19027573     DOI: 10.1016/j.jcrs.2008.08.022

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  24 in total

1.  Safety of prophylactic intracameral moxifloxacin ophthalmic solution after cataract surgery in patients with penetrating keratoplasty.

Authors:  Osman Sevki Arslan; Ceyhun Arici; Mustafa Unal; Erdogan Cicik; Mehmet Serhat Mangan; Eray Atalay
Journal:  Int J Ophthalmol       Date:  2014-10-18       Impact factor: 1.779

2.  Retinal toxicity after intracameral use of a standard dose of cefuroxime during cataract surgery.

Authors:  Céline Faure; Daniel Perreira; Isabelle Audo
Journal:  Doc Ophthalmol       Date:  2014-10-16       Impact factor: 2.379

3.  Comparison of the influence of intracameral gentamicin, gatifloxacin, and moxifloxacin on the corneal endothelium in a rabbit model.

Authors:  Shinichiro Kobayakawa; Yoshimune Hiratsuka; Yasuo Watabe; Akira Murakami; Tetsuo Tochikubo
Journal:  Jpn J Ophthalmol       Date:  2010-11-05       Impact factor: 2.447

4.  Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and vancomycin at the end of cataract surgery: a meta-analysis.

Authors:  Randy C Bowen; Andrew Xingyu Zhou; Sailaja Bondalapati; Thomas W Lawyer; Karisa B Snow; Patrick R Evans; Tyler Bardsley; Mary McFarland; Matthew Kliethermes; Dallas Shi; Christina A Mamalis; Tom Greene; Christopher J Rudnisky; Balamurali Krishna Ambati
Journal:  Br J Ophthalmol       Date:  2018-01-11       Impact factor: 4.638

5.  Endothelial Cell Toxicity of Vancomycin Infusion Combined with Other Antibiotics.

Authors:  Maryline Drouet; Feng Chai; Christine Barthélémy; Gilles Lebuffe; Bertrand Debaene; Bertrand Décaudin; Pascal Odou
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

6.  Influence of vancomycin infusion methods on endothelial cell toxicity.

Authors:  Maryline Drouet; Feng Chai; Christine Barthélémy; Gilles Lebuffe; Bertrand Debaene; Bertrand Décaudin; Pascal Odou
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

7.  Intracameral vancomycin following cataract surgery: An eleven-year study.

Authors:  Deepa R Anijeet; Prasad Palimar; Clive O Peckar
Journal:  Clin Ophthalmol       Date:  2010-04-26

Review 8.  Intracameral cefuroxime: prophylaxis of postoperative endophthalmitis after cataract surgery.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546

9.  [Intracameral moxifloxacin: a safe option for endophthalmitis prophylaxis? In vitro safety profile for intraocular application].

Authors:  M Kernt; C Hirneiss; A S Neubauer; R G Liegl; K H Eibl; A Wolf; H de Kaspar; M W Ulbig; A Kampik
Journal:  Ophthalmologe       Date:  2010-08       Impact factor: 1.059

10.  Are cefuroxime and vancomycin really safe on the corneal endothelial cells?

Authors:  Tök Y Ozlem; Demir M Necati; Yilmaz M Fatma; Yilmaz Gülsen; Nurözler B Ayşe; Ornek Firdevs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.